ENTER
  • 18th Meet The Professor. Advanced International Breast Cancer Course (AIBCC) - In-Class Course

    Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
    As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.
    New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, tio allow for a rational de-escalation or escalation of  curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
    The 18th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

  • Modalità di partecipazione

    L’iscrizione all’attività potrà avvenire esclusivamente attraverso procedura online, non saranno accettati nuovi iscritti presso la sede congressuale.

    Per l’accesso agli spazi congressuali, AccMed raccomanda di attenersi alle seguenti norme di sicurezza:

    • non accedere agli spazi congressuali con temperatura corporea superiore a 37.5
    • mantenere la distanza interpersonale
    • indossare la mascherina FFP2 coprendo naso e bocca per tutta la durata dei lavori
    • disinfettare frequentemente le mani con appositi gel idroalcolici

    Potete trovare ulteriori dettagli relativi allo svolgimento dell’evento residenziale e alle relative misure di sicurezza qui: https://fad.accmed.org/sicurezza.

  • Programma dell’attività formativa

    10.15Introduction to the ConferencePierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat
    SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION
    Chairpersons: Hesham Ahmed Gaballah Elghazaly,  Aleix Prat
    10.30Biological heterogeneity and clinical outcomes in HR+/HER2-negative diseaseMaria Vittoria Dieci
    11.00PDL1, TMB, TROP2, immune infiltration and genomic classifiers in TNBCGiampaolo Bianchini
    11.30Is HER2-low breast cancer a real entity? Scoring issues and biological heterogeneityGiuseppe Viale
    12.00HER2+ early breast cancer: potential role of genomic classifiersAleix Prat
    12.30

    Q&A

    13.00Lunch
    SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS MASTECTOMY, BREAST RECONSTRUCTION AND RADIATION THERAPY
    Chairpersons: Jaceck Jassem, Philip Poortman
    14.00When is breast-conserving therapy really not avoidableOreste Davide Gentilini
    14.30Breast reconstruction: when and how?Vincenzo Vindigni
    15.00Radiation therapy after breast reconstructionOrit Kaidar-person
    15.30

    Q&A

    Multidisciplinary Tumor Board 1 – Locoregional treatment
    Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Fedro Peccatori
    16.00Clinical case 1. Second breast conserving therapyTania Saibene
    16.15Clinical case 2. Patient with lymph node seen on planning CT-scan: what now? (RT)Silvia Michieletto
    16.30Clinical case 3: BOOP: after or due to radiation therapyLuca Visani
    16.45Concluding commentsEleftherios Mamounas, Fedro Alessandro Peccatori
    17.00

    Adjourn

    17.45Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2022
    18.00Lecture of the Awardee
    18.30

    Adjourn

    SESSION III – EARLY BREAST CANCER. FINE TUNING FROM DE-ESCALATION TO ESCALATION
    Chairpersons: Michelino De Laurentiis, Miguel Martin
    9.00Tailoring neoadjuvant/adjuvant treatment for triple negative breast cancerSibylle Loibl
    9.30Risk adapted treatment of early HR+/HER2- breast cancer: from modulation of endocrine treatment to novel agentsStephen Johnston
    10.00Is there a role for anthracyclines in contemporary treatment of early breast cancer?Valentina Guarneri
    10.30

    Q&A

    11.00Coffee Break
    Multidisciplinary Tumor Board 2 - Early breast cancer
    Panelists: Bettina Borisch, Michelino de Laurentiis, Valentina Guarneri, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Miguel Martin, Fedro Peccatori
    11.30Clinical case 1. Node positive, premenopausal patient: role of genomic classifiersCristina Falci
    11.45Clinical case 2. HR+HER2+ patient with residual disease after neoadjuvant therapyFederica Miglietta
    12.00Clinical case 3. Adjuvant treatment in rare histologiesGrazia Vernaci
    12.15Concluding commentsJacek Jassem, Miguel Martin
    12.30Lunch
    SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS
    Chairpersons: Bettina Borisch, Alessandra Gennari
    13.30HER2+ advanced breast cancer: new treatment algorithmsSandra Swain M
    14.00TN advanced breast cancer: biology-driven treatment algorithmsHope Rugo
    14.30HR+ advanced breast cancer: what after CDK4/6?Giuseppe Curigliano
    15.00

    Q&A

    Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer
    Panelists: Bettina Borisch, Pierfranco Conte, Giuseppe Curigliano, Hesham Ahmed Gaballah Elghazaly, Hope Rugo, Sandra Swain
    15.30Clinical case 1. Brain metastasesGaia Griguolo
    15.45Clinical case 2. Possibility of discontinuing treatment in very long term respondersCarlo Alberto Giorgi
    16.00Clinical case 3. Locoregional treatment for oligometastatic disease or role of NGS in ABCMichele Bottosso
    16.15Concluding commentsPierfranco Conte, Hesham Ahmed Gaballah Elghazaly
    16.30

    Take home messages and adjourn

  • Iscrizioni

    Questa attività è riservata a un numero limitato di partecipanti.

    La quota di partecipazione è gratuita.

    Per partecipare all’evento è necessario completare la procedura di iscrizione.

  • Obiettivo formativo nazionale

    Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere

  • Istruzioni ECM

    Per completare il percorso formativo e ottenere i crediti ECM previsti, l’utente deve soddisfare tutte le seguenti condizioni:

    1. Appartenere a una professione/disciplina corrispondente a quelle previste dall'accreditamento ECM;
    2. Partecipare ad almeno il 90% della durata dell’evento;
    3. Compilare la scheda di valutazione dell’evento - resa disponibile ESCLUSIVAMENTE ONLINE al termine dell’evento stesso - entro e non oltre la mezzanotte del 3° giorno successivo a quello in cui è terminata l'attività formativa;
    4. Superare con successo il test di verifica dell’apprendimento - reso disponibile ESCLUSIVAMENTE ONLINE al termine dell’evento stesso - entro e non oltre la mezzanotte del 3° giorno successivo a quello in cui è terminata l'attività formativa. Il test consiste in un questionario a risposta multipla con una sola risposta corretta per ciascuna domanda. E' consentito un solo tentativo ed è considerato superato con successo quando si risponde correttamente ad almeno il 75% delle domande.